Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Moderate to Severe Chronic Spontaneous Urticaria Subjects Inadequately Controlled by Second Generation H1-antihistamines
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
This observational or N/A phase trial investigates Chronic Spontaneous Urticaria (CSU) and is currently actively recruiting participants. Beijing InnoCare Pharma Tech Co., Ltd. leads this study, which shows 2 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
2 versions recorded-
Apr 21, 2026 — Present [daily]
Recruiting
Status: Not Yet Recruiting → Recruiting · Phase: PHASE2/PHASE3 → None
-
Feb 2026 — Apr 2026 [monthly]
Not Yet Recruiting PHASE2/PHASE3
First recorded
Eligibility Summary
The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Contact Information
- Beijing InnoCare Pharma Tech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Beijing, China , Bengbu, China , Changchun, China , Changsha, China , Chengdu, China , Chengdu, China , Chongqing, China , Chongqing, China , Fuzhou, China and 20 more locations